Posted On: AUG-2023 | Categories : Healthcare
Surgical robots are intended to improve results in open surgical procedures as well as to address the current drawbacks of minimally invasive surgery.
The market share of autonomous robots will rise from 43.8% to 46.9% by 2029 as robotic surgery technology transitions from semi-autonomous to autonomous robots.
Between 2012 and 2022, the proportion of surgical procedures in the US that were carried out using robotic technology rose from 0% to 22%.
Robotic surgery is most commonly used for the treatment of thyroid cancer (38%) and prostate cancer (27.8%).
The market for surgical robots in 2021 was USD 5.16 Bn, and by 2030, it will be worth USD 20.98 Bn, growing at a 16.84% CAGR during 2021-2030.
More people are accepting robotic surgery as a credible option for numerous medical operations. Every year, there has been an average of 25% growth in robotic surgical procedures.
•Rising Collaborations in the Global Robotic Industry
Numerous M&A transactions are happening in the robotics industry, which is expanding quickly due to both necessity and opportunity. OrthoSensor was acquired by Stryker Corporation in 2021, a leader in worldwide musculoskeletal care and sensor technologies, to improve the capabilities of Mako surgical robots and associated data analytics.
To advance its expertise in robotic surgery, Medtronic purchased London-based data analytics company Digital Surgery in 2020.
•Growing Interest in Robotic Surgery
Per WHO data, there will be 1.5 billion elderly people worldwide by 2050. There will be a greater need for knee and hip replacement surgery because rheumatoid arthritis and bone damage are more common in older persons. The rising rate of chronic diseases and traffic accidents are driving up the need for surgical robots across medical facilities.
•Development of New Products
Ongoing advancements in robotics are the result of an increase in R&D projects and the dominance of multinational rivals. Leading companies are investing in R&D initiatives to cut costs and hasten the clinical implementation of novel surgical methods. The global surgical robot market is growing due to smaller tools and affordable, high-tech robots. Hugo is a robotic-assisted surgery system that Medtronic introduced in 2022 and is intended for a variety of soft-tissue surgeries.
•Contemporary Surgical Platforms
New surgical platforms and ownership models for technology will keep coming forth. Hospital budget constraints frequently lead to the development and introduction of new healthcare technologies. New business models and affordable enabling technologies are necessary for the introduction and widespread adoption of novel medical solutions.
•Robotic surgery in ASCs
The high-volume, low-cost treatments that are generally carried out in ambulatory surgery centers (ASCs) can be supported by robotics-assisted technologies. Robotics-assisted technology reduces operating expenses by utilizing standardized reusable tools and open-platform design, which enables hospitals to make the most of their current technological investments.
•Telehealth/Telesurgery
The success of telesurgery in the future depends on the availability of 5G & broad deployment of robotics-assisted technology. Telesurgery will become a more practical alternative for some treatments as the use of 5G and robotics-assisted technology increases.
•From 2020 to 2030, there will be an increase in robotic surgical procedures in the US at a CAGR of 10.5%. By 2030, the medical robotics industry, including care robots, will generate $14.5 billion in revenue.
•In more than 8.5 million surgical procedures as of 2021, doctors have utilized the da Vinci surgical robot, and more than 6700 da Vinci Systems have been installed in hospitals throughout the world.
•By 2021, more than 6730 da Vinci surgical systems was deployed in 69 nations, and more than 10 Mn MI robotic surgeries have been carried out, of which nearly 1.5 million surgeries was conducted in 2021.
•On the Chinese mainland, more than 260 da Vinci surgical systems have been installed, and close to 300,000 operations have been carried out.
•Chinese mainland has seen an increase in the number of treatments employing the da Vinci surgical system, with 95,000 surgeries performed in 2022
•The overall number of surgeries using the da Vinci surgical system in 2022 was 1.5 million, an 15% increase from 2021.
•The overall number of surgeries using the da Vinci surgical system in 2019 was 1.2 million, an 18% increase from 2018.
•In 2020, there were over 47,400 procedures, and in 2021 there were over 89,000. The latter represents an increase of 87.8% from the prior year.
•The number of surgical procedures on the Chinese mainland increased in 2021 by more than 28% global growth rate during the same period.
•Between 2012 and 2022, the percentage of general surgery procedures using robotic surgery rose from 1.8% to 17%.
•Robotic surgery is becoming increasingly popular in various fields, with an annual growth rate of around 15%. Its global volume was 1.24 million in 2020, with the US accounting for 70.6% of total surgery.
•Over 900 new robotic platforms become operational globally each year.
•Nearly 12,000 robotic surgeries were carried out by these centers in 2018, 83.4% of which were urological procedures.
•Putting in place a new robotic surgical platform might cost more than $1 million, plus an additional $3,500 to $5,000 for each surgical session.
•With a 50% increase in labor productivity, the robotic approach raised hospital-level total production by 22% to 36%.
•Currently, there are 1Mn minimally invasive robotic surgery procedures conducted globally.
•On average robotic surgery have a 95% success rate.
•The surgical instruments and accessories segment has the largest share of 53%. In 2021, they were estimated to be worth about USD 3.6 billion. The market is dominated by robotic systems (41%), followed by services (6%).
•Robotic surgery is dominated by Intuitive Surgical, which has an 85% market share and a market valuation of $115 billion. The Da Vinci robotic system, the company's flagship product, has been used in 8.5 million operations worldwide.
•The robotically-assisted devices market is categorized into robotically assisted systems (RAS), tools & accessories, and services/maintenance contracts. The market for instruments and accessories was the largest, growing at an 18.3% share, and is worth $5.1 billion in 2023.
•With a CAGR of 14.6%, sales of robotic-assisted systems, which now rank second in the market overall, will reach $3.3 billion in 2023. In 2023, service revenue will expand at a CAGR of 11.7% and reach $1.3 billion.
•In 2022, the market share for robotic surgery in general surgery applications was 23%, followed by orthopedic surgery and gynecology.
•By 2030, the market for surgical robots will be led by general surgery, with an 87% share.
•Additionally, pediatric patients are rapidly undergoing robotic surgery, with urological treatments accounting for the majority of cases (51%), followed by gynecological procedures (22%) and oncological surgeries (12%).
•The most frequent uses of robotic surgery are for thyroid and prostate cancer surgeries, which account for 38% and 27.8% of operations.
•Around 11% of knee repair operations were conducted in 2020 with robotic assistance. By 2030, there will be over 700,000 robotic-assisted knee reconstruction procedures performed worldwide, growing at a CAGR of 8% from 2021 to 2030.
•By 2030, the orthopedic robotics market will be worth USD 750 Mn due to the rising number of knee replacement surgery assisted by robots.
•Neurosurgery is a rapidly growing sector expanding at a 10.5% CAGR from 2020-2030.
•The market for neurosurgical robotics in 2021 was worth USD 1,691.02 Mn, and by 2028 it will reach USD 4,729 Mn, growing at a 16.2% CAGR during 2022-2028.
•Robotic-assisted prostatectomy is a well-established procedure in urology, with approximately 80% of surgeries in the United States using robotic assistance.
•During the forecast period of 2023-2030, the market for urology robotics surgery will grow at an 11.5% CAGR.
•Inguinal hernia repair (28.8%), proctectomy (26.7%), reflux surgery (26%), ventral hernia repair (22.4%), colectomy (16.3%), and cholecystectomy (7.5%) are common general surgery procedures that use robotic surgery.
•In the first four years following hospitals' introduction of the operation, the use of robotic surgery increased by 8.8%, while laparoscopic procedures decreased by 53.2% to 51.3%.
•Hospitals have been increasing the utilization of laparoscopic surgery by 1.3% annually.
•Robotic surgeries in general surgery increased by 30% in the US in 2019 and decreased by 6% in 2020.
•Robotic procedures for gynecologic procedures increased by 6.5% in 2022.
•For urological treatments, the surgical robot market was worth USD 1.6 billion in 2021 and will reach USD 4.3 billion in 2028.
•282,000 gynecologic surgery treatments, 138,000 urologic procedures, and 421,000 general surgery procedures were all carried out in the US using the da Vinci. This represents nearly 48% of all da Vinci procedures performed in the US.
•The market for robot-assisted surgical systems in North America reached USD 2.8 billion in 2021, and by 2028, the market will reach USD 7 billion, growing at a 14.9% CAGR.
•In 2021, the US market was worth USD 2.4 billion, making it the largest market globally. The US market made up 35% of the worldwide market and 85% of the market in the region.
•In the US, there were more than 114,000 procedures overall in 2019. Hip surgeries increased 40% last year, while knee procedures increased 66% to 75,000 in 2019.
•The number of robotic procedures carried out in the United States in 2018 was 753,000, 883,000 in 2019, and 876,000 in 2020.
•Europe and Asia Pacific are two significant markets, with a share of 30% and 21% in 2021.
•The market for robotic surgery services in the UK in 2022 was USD 112 million, and by 2030, it will be worth USD 400 million, growing at a 17.30% CAGR.
•There are about 115 da Vinci systems in the UK, which span most of the continents.
•The market size for robotic surgery services in Germany was USD 157 million in 2022, and by 2030, it will reach USD 570 million, growing at a 17.5% CAGR from 2022 to 2030.
•In 2005, 1079 robotic-assisted procedures were carried out in German medical facilities. The number climbed to 37,876 by 2020, with a CAGR of 26.8%.
•Asia Pacific is growing faster than the rest of the world with a CAGR of 15.9% due to the rising demand from important markets like China and Japan, the expansion of the patient base in India, the emergence of advanced healthcare services by governments, and joint R&D efforts by universities and governments.
•China exhibits the fastest market growth among all other nations, with a CAGR of 16.5%. By 2021, there were over 260 da Vinci Surgical Systems installed in China. More than 260 installations were made in 2021. China's surgical robot market will increase from USD 399 million in 2021 to USD 1.1 billion by 2028.
•The market size for robotic surgery services in Japan was USD 267 million in 2022, and by 2030, it will reach USD 1131 million, growing at a 19.8% CAGR from 2022 to 2030.
•In 2022, nearly 12,000 robotic-assisted surgeries were performed in India.
•In India, the success rate of robotic surgery is nearly 94%-100%.
•Apollo Hospitals conducted over 450 robotic procedures in India in the first two months of 2023, and this number will rise dramatically throughout the year.
•Over six billion people worldwide do not have access to the advantages of robotic surgery since 87% of the surgical robotic systems installed globally are now located in the US, Europe, and Japan.
1.How many robotic surgeries have been performed?
2. How many robotic surgeries were performed in the USA?
3. How many Gynecological Robotic Surgery are performed?
4. How many urologic Robotic Surgery are performed?